Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma

Phase

N/A

Condition

Bone Diseases

Leukemia

Multiple Myeloma

Treatment

VascuTherm5 vascular compression device

Clinical Study ID

NCT03870451

IRB00056641

WFBCCC 01119

NCI-2019-01261

P30CA012197

Ages > 18
All Genders

Study Summary

This trial studies how well cryocompression therapy works in reducing bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Peripheral neuropathy (nerve pain or tingling in hands or feet) is a common side effect of chemotherapy such as bortezomib that affects the quality of life and amount of chemotherapy that can be given to many cancer patients. Cryocompression is a treatment where a glove and a boot are worn to cool down the skin. This cooling treatment is safe and does not interfere with chemotherapy treatment. Daily cryocompression therapy may reduce neuropathy caused by bortezomib chemotherapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Patients must have histologically or cytologically confirmed multiple myeloma (anyInternational Staging System [ISS] stage).
Clinical symptoms of bortezomib-induced peripheral neuropathy as measured by theNCI-CTCAE.

Cohort 1: Patients with clinically documented CTCAE grade greater than or equal 2 neuropathy.

Cohort 2: Patients with clinically documented CTCAE grade 1-2 neuropathy.

• Currently or previously received bortezomib-containing regimen

Cohort 1: Patients who have previously received a bortezomib-containing regimen and have clinically documented neuropathy that is attributed to the bortezomib containing regimen.

Cohort 2: Patients who are currently receiving a bortezomib-containing regimen and have clinically documented neuropathy that is attributed to the bortezomib containing regimen.

Age must be greater than or equal to 18 years.
Eastern Cooperative Oncology Group (ECOG) =< 4.
Life expectancy >= 6 months.
Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document.

Exclusion

Exclusion Criteria:

Self-reported or documented history of pre-existing peripheral neuropathy prior toinitiation of bortezomib therapy.
Other explanatory etiology for neuropathy.
Presumptive evidence of congestive heart failure.
Current deep vein thrombosis or pulmonary embolism (diagnosed within the past 6months).
Current pulmonary edema.
Unable to provide accurate medical history.
Pregnant women are excluded from this study because they will not be receivingmyeloma standard of care (SOC) therapy or bortezomib-based therapy per inclusioncriteria.
Current or previously documented inflammatory phlebitis; thrombophlebitis;decompensated cardiac insufficiency; arterial dysregulation; erysipelas; carcinomaor carcinoma metastasis in the affected extremity; decompensated hypotonia; venousor arterial occlusive disease; or Raynaud's disease;
Current monoclonal gammopathy of undetermined significance (MGUS), Waldenstromsmacroglobulinemia, or Castleman disease.

Study Design

VascuTherm5 vascular compression device

November 01, 2019

February 10, 2023

Study Description

PRIMARY OBJECTIVES:

I. To assess the feasibility of daily cryocompression therapy in multiple myeloma patients with bortezomib-induced peripheral neuropathy (BIPN).

SECONDARY OBJECTIVES:

I. To examine the change in patient-reported assessment of neuropathy based on the sensory, motor and autonomic neuropathy scores on the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Cancer-Induced Peripheral Neuropathy (CIPN20) (patient-reported outcome [PRO]) from baseline to 4 and 8 weeks after the start of cryocompression therapy.

II. To examine the change in physician graded assessment of peripheral neuropathy by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 criteria from baseline to 4 and 8 weeks after the start of cryocompression therapy.

III. To assess the effect on sensory and motor nerve function via nerve conduction study (NCS) (e.g. conduction velocity, latency, and amplitude) and neuro-ultrasound after 8 weeks of daily cryocompression therapy.

EXPLORATORY OBJECTIVES:

I. To explore the effect of 8 weeks of cryocompression on changes in digital artery perfusion as measured by ultrasound (US).

II. To examine the associations among the peripheral nerve assessment measures (nerve conduction and peripheral nerve US) with the patient reported outcomes (EORTC QLQ-CIPN20, PRO-CTCAE) at baseline, week 4, week 8, and for the change from baseline to week 8.

OUTLINE:

Patients undergo home cryocompression therapy treatments on their non-dominant hand and foot over 30 minutes daily for 8 weeks.

After completion of cryocompression therapy, patients are followed up at 30 days.

Connect with a study center

Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina 27157
United States
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.